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Dr	K.	Howe	(Now	at	the	Wellcome	Trust	Sanger	Institute	and	formerly	of	the	Cancer	Research	UK	Cambridge	Institute)	developed	the	first	generation	of	the	pipeline	discussed	in	this	chapter.	This	pipeline,	termed	structural	variation	from	SAM	(SVFS),	used	discordant	read	pair	clustering	to	identify	possible	structural	variants.	Reads	were	first	aligned	using	BWA	and	duplicates	were	flagged	using	PICARD	and	removed	from	further	processing.	Three	categories	of	aberrant	read	pairs	are	then	identified	for	further	analysis:	1.) Discordant	read	pairs	i.e.	those	mapping	to	two	different	chromosomes,	in	the	wrong	orientation	or	too	great	a	distance	apart	2.) Single	end	mapping	reads	i.e.	those	where	one	read	of	the	pair	has	a	normal	mapping	whilst	the	other	is	unable	to	be	mapped	uniquely	to	the	reference	genome	3.) Unmapped	read	pairs	i.e.	those	read	pairs	in	which	neither	read	of	the	pair	is	able	to	be	uniquely	mapped	to	the	reference	genome	Read	pairs	that	meet	any	of	the	above	criteria	are	passed	to	Novoalign,	for	a	second	round	of	alignment	with	flags	set	as	in	Methods.	Novoalign	is	a	more	precise	short	read	mapper	utilising	the	Needleman-Wunsch	algorithm	for	alignment	for	all	reads	whilst	in	BWA	a	more	complex	alignment	(Smith-Waterman	in	this	case)	is	reserved	for	the	unmapped	partner	of	a	mapped	read,	where	the	search	space	can	be	restricted	to	sequence	local	to	the	mapped	partner	read.	Discordant	read	pairs	are	identified	from	the	resulting	Novoalign	output	and	passed	to	a	Perl	script	for	clustering.	In	the	clustering,	steps	reads	are	identified	that	lie	within	the	maximum	insert	size	of	each	other	and	are	in	the	same	orientation.	The	genomic	position	of	partner	reads	of	each	read	within	the	cluster	is	determined	and	an	SV	is	identified	if	at	least	3	reads	within	the	cluster	also	show	clustering	of	their	partner	reads.	If	a	matched	normal	sample	has	been	
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#Calculate	the	frobenius	reconstruction	error	for	each	of	the	factorization	ranks	#chosen	reconstructerrorlist	<-	list()	q	=	1	while	(q<10)	{				 print	(q)	q	=	q	+	1	#extract	the	matrix	of	mean	mutation	contributions	to	each	potential	signature	PP	<-	resultsclustmatrixmeanSig[[q]]	PPmat	<-	matrix(unlist(PP),	ncol	=	96,	byrow	=	TRUE)	#extract	the	matrix	of	the	mean	contribution	of	each	signature	to	each	sample			EE	<-	resultsclustmatrixmeanallE[[q]]	EEmat	<-	(matrix(unlist(EE),	ncol	=	43,	byrow	=	TRUE))	#calculate	the	frobenius	reconstruction	error	for	each	factorization	rank	by;		#1.)	multiplying	the	two	matrices	together	to	reconstruct	the	original		#2.)	subtracting	that	from	the	original	data	matrix			 reconstruct<-t(EEmat)%*%PPmat			 remenant	<-	mydata	-	reconstruct	reconstructerror	<-	norm(as.matrix(remenant),"F")	reconstructerrorlist[[q]]	<-	reconstructerror	}	The	remaining	appendix	items	are	available	on	the	attached	DVD	due	to	size	constraints	and	for	ease	of	viewing	Perl	and	R	code.	Appendix	1.2:	Perl	script	for	extracting	sequence	context	for	a	list	of	mutations	Appendix	1.3:	Perl	script	for	summarizing	context	data	from	a	list	of	mutations	Appendix	1.4:	Perl	script	for	extracting	sequence	for	SV	primer	design	
Appendix	2:	Additional	Data	tables	Appendix	Table	2.1:	Clinical	data	and	mutation	signature	exposures	for	structural	variants	and	single	nucleotide	variants	Appendix	Table	2.2:	All	structural	variants	from	43	tumours	Appendix	Table	2.3:	Mutation	context	summarized	all	43	tumours	Appendix	Table	2.4:	SV	verification	results	Appendix	Table	2.5:	False	positive	SVs	following	verification	
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